Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22… – Press Release

[ad_1]

Regulatory News:

Sensorion ALSEN (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in person of Sensorion’s management in the Bioprocessing Summit Europe, held in person and virtually on March 22-24, 2022 in Barcelona, Spain.

Christine Le Bec, Head of CMC Gene Therapy, will chair a session entitled “Navigating Gene Therapy CMC and Analytics” at 2.25 am – 6.00 am EDT (8.25 am – 12 am CET) on Tuesday, March 22nd.

Otmane Boussif, Chief Technical Officer, will chair a session entitled “Gene Therapy Analytics” at 7.30 am -11.15 am EDT (1.30 pm – 5.15 pm CET), on Tuesday, March 22nd where Christine Le Bec will give a talk, in person, the same day, on the “Characterization of Dual AAV Vector Otoferlin” at 8.05 am – 8.35 am EDT (2.05 pm – 2.35 pm CET).

Otmane Boussif will also facilitate an in-person interactive discussion entitled “Gene Therapy CMC and Development” at 11.15 am – 12 am EDT (5.15 pm – 6 pm CET) the same day.

The agenda of the conference can be found here.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates, and has a pipeline of small molecule and gene therapy-based programs.

Sensorion is assessing next steps to advance clinical development of SENS-401 for SSNHL and for cisplatin-induced ototoxicity (CIO). Sensorion is advancing, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.

Sensorion has entered into a broad…

[ad_2]